Cyberknife stereotactic body radiotherapy for liver metastases from prostate cancer.
- Author:
Ze-Tian SHEN
1
;
Han ZHOU
2
;
Xiao-Qin JI
1
;
Ao-Mei LI
1
;
Bing LI
1
;
Xi-Xu ZHU
1
;
Rui WANG
1
;
Long-Bang CHEN
3
Author Information
1. Department of Radiation Oncology,Jinling Hospital, Jinling Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210002, China.
2. Department of Radiation Oncology, Jinling Hospital, Jinling Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210002, China.
3. Department of Medical Oncology, Jinling Hospital, Jinling Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- Keywords:
Cyberknife;
liver metastasis;
prostate cancer;
stereotactic radiation therapy
- From:National Journal of Andrology
2019;25(5):333-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effectiveness and adverse effects of Cyberknife stereotactic body radiotherapy (SBRT) on liver metastases from PCa.
METHODS:From June 2009 to September 2016, we treated 20 cases of PCa liver metastases by Cyberknife SBRT, at a total dose of 36 (30－50) Gy, on 1－3 liver metastatic lesions, for 3－5 times, with a prescription isodose line of 70－92%. We assessed the therapeutic effect according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), calculated the survival and disease-control rates using the Kaplan-Meier method, and analyzed the adverse events based on the National Cancer Institute Common Terminology Criteria for Adverse Events－Version 4.0 (CTCAE 4.0).
RESULTS:Of all the cases treated, complete response (CR) was found in 8 (40.0%), partial response (PR) in 9 (45.0%), stable disease (SD) in 2 (10.0%), and progressive disease (PD) in 1 (5.0%), with a local control rate (CR+PR) of 85.0% and a disease-control rate (CR+PR+SD) of 95.0%. Among the 14 patients with elevated PSA, 10 (71.4%) showed a significant decrease after treatment. The median follow-up time was 17 months, the 1- and 2-year survival rates were 85.0% and 15.0%, respectively, and the median survival time of the 20 patients was 16.5 months (95% CI: 12.12－22.88). Cyberknife SBRT was well tolerated in all the patients, with only a few mild adverse events (mainly grades 1 and 2 but no 4 and 5) during the whole course of treatment.
CONCLUSIONS:Cyberknife SBRT is safe and effective in the treatment of PCa liver metastases, with a high local control rate, and capable of reducing the PSA level and raising the long-term survival rate of the patients.
